CN1158287C - Benzothieno [3,2-c]pyridines as alpha 2-antagonists - Google Patents
Benzothieno [3,2-c]pyridines as alpha 2-antagonists Download PDFInfo
- Publication number
- CN1158287C CN1158287C CNB998116777A CN99811677A CN1158287C CN 1158287 C CN1158287 C CN 1158287C CN B998116777 A CNB998116777 A CN B998116777A CN 99811677 A CN99811677 A CN 99811677A CN 1158287 C CN1158287 C CN 1158287C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention concerns the compounds of formula (I), the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein each R<1> is independently hydrogen, halogen, C1-6 alkyl, nitro, hydroxy or C1-4 alkyloxy; Alk is C1-6 alkanediyl; n is 1 or 2; p is 0, 1 or 2; D is an optionally substituted mono-, bi- or tricyclic nitrogen containing heterocycle having central alpha 2-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine.
Description
Technical field
The present invention relates to have maincenter α
2The active thionaphthene of-adrenergic receptor antagonist is [3,2-c] pyridine derivate also.The present invention relate in addition they the preparation method, comprise their composition and they are as the purposes of medicine.
Background technology
Known maincenter α
2-adrenoceptor antagonists is by blocking-up presynaptic α
2-acceptor increases norepinephrine and discharges, and this receptor performance suppresses the control action kou to release neurotransmitters.By increasing the concentration of norepinephrine, α
2-antagonist can be used in clinically treatment or prevention dysthymia disorders, cognitive disorder, Parkinson's disease, diabetes, sexual dysfunction and impotence, rising intraocular pressure and with the intestinal peristalsis diseases associated of disorder because all these diseases all lack relevant with norepinephrine in central or peripheral nervous system.
Summary of the invention
The compounds of this invention is new and to α
2The different known hypotype of-adrenoceptor is α
2A, α
2BAnd α
2C-adrenoceptor has specificity and selective binding avidity.
The present invention relates to following formula: compound, their N-oxide form, pharmaceutically acceptable addition salt and form of three-dimensional chemical isomer,
Wherein:
Each R
1Independent is hydrogen, halogen, C
1-6Alkyl, nitro, hydroxyl or C
1-4Alkoxyl group;
Alk is C
1-6Alkane 2 basis;
N is 1 or 2;
P is 0,1 or 2;
D be 1-or 2-benzimidazolyl-, 2 (group of 3H) benzoxazolone-3-base or following formula:
Wherein
Each X independently represents O, S or NR
12
R
2Be hydrogen, C
1-6Alkyl, aryl or aryl C
1-6Alkyl;
R
3Be hydrogen, C
1-6Alkyl, C
1-6Alkoxyl group, C
1-6Alkylthio, amino or list-or two (C
1-6Alkyl) amino;
R
4, R
5, R
6, R
7, R
8, R
10, R
11And R
12Each independently is hydrogen or C
1-6Alkyl;
R
9Be hydrogen, C
1-6Alkyl or aryl; Or
R
3And R
4Can form the divalent group-R of following formula together
3-R
4-:
-CH
2-CH
2-CH
2- (a-1)；
-CH
2-CH
2-CH
2-CH
2- (a-2)；
-CH＝CH-CH
2- (a-3)；
-CH
2-CH=CH-(a-4) or
-CH＝CH-CH＝CH- (a-5)；
One or two hydrogen atom of wherein said group (a-1) to (a-5) each can be independently by halo, C
1-6Alkyl, aryl C
1-6Alkyl, trifluoromethyl, amino, hydroxyl, C
1-6Alkoxyl group or C
1-10Alkyl carbonyl oxy substitutes; Perhaps if possible, two paired hydrogen atoms can be by C
1-6Alkylidene group or aryl C
1-6Alkylidene group substitutes; Perhaps
-R
3-R
4-also can be:
-S-CH
2-CH
2- (a-6)；
-S-CH
2-CH
2-CH
2- (a-7)；
-S-CH＝CH- (a-8)；
-NH-CH
2-CH
2- (a-9)；
-NH-CH
2-CH
2-CH
2-?(a-10)；
-NH-CH＝CH- (a-11)；
-NH-CH＝N- (a-12)；
-S-CH=N-(a-13) or
-CH＝CH-O- (a-14)；
Wherein in described group (a-6) to (a-14) or if possible two or three hydrogen atoms each can be independently by C
1-6Alkyl or aryl substitutes; And aryl is a phenyl or for to be selected from halo, hydroxyl, nitro, cyano group, trifluoromethyl, C with, two or three
1-6Alkyl, C
1-6Alkoxyl group, C
1-6Alkylthio, sulfydryl, amino, list-and two (C
1-6Alkyl) amino, carboxyl, C
1-6Alkoxy carbonyl and C
1-6The phenyl that the substituting group of alkyl-carbonyl replaces.
As using in the definition formerly, term halogen is the general name to fluorine, chlorine, bromine and iodine.Term C
1-6Alkyl is defined as the straight chain with 1 to 6 carbon atom and the stable hydrocarbon of side chain, for example, and methyl, ethyl, propyl group, butyl, 1-methylethyl, 1,1-dimethyl ethyl, 2-methyl-propyl, amyl group, hexyl etc.Term C
1-10Alkyl is intended to comprise C
1-6Alkyl and their more high-grade homologue with 7 to 10 carbon atoms, for example, heptyl, octyl group, nonyl, decyl etc.Term C
1-6Alkane 2 basis is defined as the alkane 2 basis of the straight or branched of the divalence with 1 to 6 carbon atom, for example, and methylene radical, 1,2-ethane two bases, 1,3-propane two bases, 1,4-butane two bases, 1,5-pentane two bases, 1,6-hexane two bases etc.; Term C
1-6Alkylidene group is defined as the alkylidene group of the straight or branched of the divalence with 1 to 6 carbon atom, for example, and methylene radical, ethylidene, 1-propylidene, 1-butylidene, 1-pentylidene, 1-hexylidene etc.
Be intended to comprise the additive salt form of the therapeutic activity that formula (I) compound can form with following suitable acid, for example acid such as mineral acid such as haloid acid example hydrochloric acid or Hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid as additive salt referred in this; Perhaps for example acid such as acetate, propionic acid, oxyacetic acid, lactic acid, pyruvic acid, oxalic acid, propanedioic acid, succsinic acid, toxilic acid, fumaric acid, oxysuccinic acid, tartrate, Citric Acid, methylsulfonic acid, ethyl sulfonic acid, Phenylsulfonic acid, tosic acid, cyclohexane sulfamic acid, Whitfield's ointment, para-aminosalicylic acid, pamoic acid of organic acid.
The metal that can form as non-toxic bases, especially formula (I) compound that is also intended to comprise therapeutic activity at pharmaceutically acceptable addition salt mentioned above or the additive salt form of amine.By handling formula (I) compound that contains acid hydrogen atom with suitable organic and mineral alkali, can obtain described salt expediently, for example ammonium salt, basic metal and alkaline earth salt, as lithium, sodium, potassium, magnesium, calcium salt etc., with the salt of organic bases such as benzyl star (benzathine), N-methyl D-glycosamine, breathe out amine (hydrabamine) and with the salt of amino acid such as arginine, Methionin etc.
By with suitable alkali or acid treatment, described salt form can be reversed its free acid or the alkali form of turning to.
As also comprise at the term additive salt that above uses solvate that formula (I) compound can form and as described in solvate be intended to be included in the scope of the present invention.The example of such solvate is for example hydrate, alcohol adduct etc.
The N-oxide form of formula (I) compound is intended to comprise that one of them or several nitrogen-atoms are oxidized to those formulas (I) compound of so-called N-oxide compound.
Term form of three-dimensional chemical isomer as used herein is defined as all possible isomeric forms that its Chinese style (I) compound can exist.Unless otherwise mentioned or indicate, the chemical name of compound refers to the mixture of all possible form of three-dimensional chemical isomer, and described mixture comprises all diastereomers and the enantiomorph of basic molecular structure.
Some formulas (I) compound also can their tautomeric forms exist.Although do not spell out in following formula, such form plans to be included in the scope of the present invention.
No matter when use hereinafter, term formula (I) compound is also intended to comprise N-oxide form, pharmaceutically acceptable addition salt and all stereoisomer forms.
Aryl is suitably phenyl or by halo or C
1-6The phenyl that alkyl replaces.
The compound of a particular group for those wherein p be 0 formula (I) compound.
One group of interesting compound for those wherein n be 1 and R
1Be hydrogen, chlorine, fluorine, methyl, methoxyl group or nitro, particularly R
1Be hydrogen or chlorine; Perhaps wherein n is 2 and two
R
1Formula (I) compound for methoxyl group.R
1Optimum position is 7 and 8 as described below.
The interesting compound of another group for those wherein Alk be methylene radical, 1,2-ethane two bases, 1,3-propane two bases, 1,4-butane two bases or 1,5-pentane two bases, particularly 1,2-ethane two bases, 1,3-propane two bases, 1,4-butane two bases, more especially 1, formula (I) compound of 2-ethane two bases.
Another group of interesting compound for those wherein D be formula (a) and (b), (c), (d) or (f) formula of group (I) compound.
Special compound is those formulas (I) compounds, and wherein D is R wherein
2Be C
1-6Alkyl, aryl or aryl C
1-6Alkyl, and R
3And R
4Form formula-R
3-R
4-divalent group and-R
3-R
4-be suitably formula (a) group of formula (a-5) or formula (a-8) group; Perhaps D is R wherein
5And R
6Be C
1-6The formula of alkyl (b) group; Perhaps D is R wherein
7Formula (c) group for hydrogen; Perhaps D is R wherein
8Formula (d) group for hydrogen; Perhaps D is R wherein
10For hydrogen and X are formula (f) group of O or S, particularly S.
Preferred compound for those wherein n be 1 and R
1Be hydrogen or chlorine, p is 0, and Alk is 1, and 2-ethane two base and D are formula (a) and (b), (c), (d) or (f) formula of group (I) compound.
Most preferred is compound described below or their N-oxide form, pharmaceutically acceptable addition salt and form of three-dimensional chemical isomer:
According at EP-A-0,037,265, EP-A-0,070,053, EP-A-0, in 196,132 and at EP-A-0,378, the method of describing in 255, by using formula (III) alkylating reagent with also [3,2-c] the pyridine derivate N-alkylation of formula (II) thionaphthene, usually can preparation formula (I) compound.At alkali for example in the presence of the yellow soda ash and choose wantonly at catalyzer and for example in the presence of the potassiumiodide, for example in the methyl iso-butyl ketone (MIBK) two intermediates are reacted easily in The suitable solvent.
In intermediate (III), W
1The reaction leavings group that expression is suitable, for example halo such as chlorine, bromine or iodine; Sulfonyloxy such as mesyloxy, 4-Methyl benzenesulfonyl oxygen base.
In this reaction and following reaction, can be from reaction medium reaction product isolated, and if necessary, be further purified according to the common known method in this area such as extraction, crystallization, grinding and chromatography.
P is blocking group such as C by inciting somebody to action wherein
1-4The N-protected intermediate of the formula of alkoxy carbonyl (IV) removes protection, and uses wherein W subsequently
2For the formula V acyl derivative of suitable reaction leavings group such as halogen the intermediate N acylations that generates, can prepare D wherein and be formula (I) compound by formula (e) group of formula (I-e) expression.For example in the presence of the yellow soda ash, in The suitable solvent such as chloroform, methyl iso-butyl ketone (MIBK) or alcohol, can carry out described reaction at alkali.
By using wherein W
3Be the amine N-alkylation of formula (VII) intermediate of suitable reaction leavings group such as halogen, can prepare D wherein and be formula (I) compound by formula (f) group of formula (I-f) expression with formula (VI).
According to functional group conversion reaction known in the art, formula (I) compound can be transformed each other.
According to conversion trivalent nitrogen known in the art is the method for its N-oxide form, also formula (I) compound can be converted into corresponding N-oxide form.Raw material by making formula (I) and suitable organic or inorganic peroxide reactions can be carried out described N-oxidizing reaction usually.Suitable inorganic peroxide for example comprises hydrogen peroxide, basic metal or alkaline earth metal peroxide such as sodium peroxide, Potassium peroxide; Suitable organo-peroxide can comprise peroxy acid such as benzoyl hydroperoxide or halo benzoyl hydroperoxide such as 3-chloro-peroxy benzoic acid, peroxide bond alkanoic acid such as peracetic acid, alkyl peroxide such as tertbutyl peroxide.The suitable solvent for example is the mixture of water, low-level chain triacontanol such as ethanol etc., hydrocarbon such as toluene, ketone such as 2-butanone, halohydrocarbon such as methylene dichloride and these solvents.
Multiple intermediate and raw material are available on the market or are can be according to the known compound of means known in the art preparation.
For example, at EP-A-0, in 037,265, EP-A-0,070,053, EP-A-0,196,132 and at EP-A-0, some formulas (III) intermediate and their preparation method are described in 378,255.
With (J.Am.Chem.Soc., 1953, the 697 pages) or US-3 such as Capps, the similar approach of describing in 752,820, can preparing wherein, X is formula (II) intermediate of S.
In flow process 1, the concrete route of synthesis of preparation formula (II) intermediate is described.
Flow process 1
With with in Heterocycles (1981), the similar approach of describing in 37, the 979-982 pages or leaves can be carried out step a.The cumarone that generates from step c is at US 4,210, is used as intermediate in 655.Other reactions steps is similar at US 3,752, the reaction method of describing in 820.
Perhaps, use the reactions steps of in flow process 2, describing, can preparation formula (II) intermediate.
Flow process 2
With with in Heterocycles (1994), 39 (1), the similar method of describing in the 371-380 page or leaf can be carried out step a.With with in J.Med.Chem. (1986), 29 (9), the similar method of describing in the 1643-1650 page or leaf can be carried out step b.With with in J.Heterocycl.Chem. (1979), the similar method of describing in 16, the 1321 pages can be carried out other reactions steps.
Some formulas (I) compound in the present invention and some intermediates comprise at least one unsymmetrical carbon.By using methods known in the art, can access the pure form of three-dimensional chemical isomer of described compound and described intermediate.For example, by physical method such as selective crystallization or chromatographic technique such as methods such as adverse current distribution, liquid phase chromatography, can separate diastereomer.By at first with suitable resolution reagent as chiral acid with as described in racemic mixture be converted into the mixture of diastereoisomeric salt or compound; Then by for example selective crystallization or chromatographic technique for example method such as liquid phase chromatography physically separate the mixture of described diastereoisomeric salt or compound; At last described isolating diastereoisomeric salt or compound are converted into corresponding enantiomorph, can from racemic mixture, obtain enantiomorph.
From the pure form of three-dimensional chemical isomer of suitable intermediate and raw material, also can obtain the pure form of three-dimensional chemical isomer of formula (I) compound, condition is that intermediate reaction takes place with stereospecificity.The pure plan with the blended form of three-dimensional chemical isomer of formula (I) compound is included in the scope of the present invention.
Formula (I) compound, their N-oxide compound, pharmaceutically acceptable addition salt and form of three-dimensional chemical isomer blocking-up presynaptic α on the maincenter noradrenergic neuron
2Therefore-acceptor increases the release of norepinephrine.Block described acceptor and lack relevant symptom suppressing or alleviating norepinephrine multiple and in central or peripheral nervous system.Use the intraocular pressure of the indication of The compounds of this invention treatment as dysthymia disorders, cognitive disorder, Parkinson's disease, diabetes, sexual dysfunction and impotence and rising.
The α of blocking-up in central nervous system
2Acceptor also shown enhancing can increase release to the serotonin for the treatment of depression effect (Maura etc., 1992, Naunyn-Schmiedeberg ' sArch.Pharmacol., 345:410-416).
Also shown blocking-up α
2Acceptor can be induced the increase into the outer DOPAC (3,4-dihydro-toluylic acid) of born of the same parents of the metabolite of Dopamine HCL and norepinephrine.
In view of motif compound norepinephrine in treatment and central nervous system lacks the especially purposes in dysthymia disorders and the Parkinson's disease of diseases associated, the invention provides treatment and suffer from the particularly method of dysthymia disorders and Parkinsonian warm-blooded animal of such disease, described method comprises that whole body treats the formula of significant quantity (I) compound or their pharmaceutically acceptable addition salt.
The compounds of this invention is a potentially useful in treatment Alzheimer and dementia also, because known α
2The release of-antagonist promotion vagusstoff (Tellez etc., 1997, J.Neurochem.68:778-785).
Effective therapeutic dose of generally estimating every day will be that about 0.01mg/kg is to about 4mg/kg body weight.
Therefore the present invention also relates to as above defining formula (I) compound that is used as medicine.In addition, the present invention also relates to the purposes that formula (I) compound is used to prepare treatment dysthymia disorders or Parkinson's disease medicine.
Ex vivo and the conduction of extracorporeal receptor signal and receptors bind research can be used for estimating the α of The compounds of this invention
2Adrenoceptor antagonism mechanism.As maincenter α in the body
2The index of adrenoceptor blocking-up can use reverse and the inhibition reserpine inductive rat that observed righting reflex effect is lost on rat behind the intravenous injection xylazine to tremble.
The compounds of this invention also has the ability of rapid permeability in the central nervous system.
For administration, motif compound can be mixed with and multiplely comprise pharmaceutically acceptable carrier and as activeconstituents, the medicinal compositions of formula (I) compound of treatment significant quantity.Be preparation medicinal compositions of the present invention, the particular compound of the significant quantity that exists with additive salt or with free acid or alkali form is mixed into mixture closely as activeconstituents and pharmaceutically acceptable carrier, and fixed its can adopt form widely according to the needed dosage form of administration.These medicinal compositionss are preferably and are suitable for being preferably oral, subcutaneous or through the unit dosage of non-enteron aisle drug administration by injection.For example, in the composition of preparation oral dosage form, any conventional medicinal medium can be used, for example in the situation of oral liquid such as suspensoid, syrup, elixir and solution, for example water, dibasic alcohol, oils, alcohols etc. can be used; Perhaps in the situation of pulvis, pill, capsule and tablet, can use as solid carriers such as starch, sugar, kaolin, lubricant, tackiness agent, disintegrating agents.Because they are easy to administration, tablet and capsule are represented best oral unit dosage form, in this case, obviously use the solid medicinal carrier.For non-enteron aisle composition, described carrier comprises aqua sterilisa usually, and is most of at least, although can comprise other composition, for example helps the dissolved composition.For example, can prepare the injection liquid that carrier wherein comprises the mixture of salt brine solution, glucose solution or salt solution and glucose solution.Can be in the oil of prolongation effect, preparation contains the injection liquid of formula (I) compound.The suitable oil that is used for this purpose is for example peanut oil, sesame oil, Oleum Gossypii semen, Semen Maydis oil, soya-bean oil, synthetic long-chain fat acid glyceride and these oil and other oily mixture.Also injection suspension can be prepared, appropriate liquid carrier, suspension agent etc. can be used in this case.In being suitable for the composition of subcutaneous administration, optional penetration enhancers and/or the suitable wetting agent of comprising of carrier, additive optional and with any character that suits of minimum proportion mixes, and described additive does not cause any tangible deleterious effect to skin.Described additive can promote percutaneous drug delivery and/or can help to prepare needed composition.These compositions can number of ways for example as through the skin patch, as drops (spot-on) or as the ointment administration.Because the water-soluble of their increase surpasses corresponding free alkali or free acid form, additive salt (I) is obviously more stable in the aqueous composition preparation.
It is particularly advantageous preparing the medicinal compositions with the unit dosage that is easy to administration and uniform dose referred to above.Refer to the physics individual that is suitable for as unitary dose as the unit dosage that uses in this specification sheets and claims, per unit comprises the amount of the pre-determining activeconstituents with the therapeutic action pharmaceutical carrier that requires, that the calculating generation is required.The example of such unit dosage is tablet (comprising tablet indentation or dressing), capsule, pill, pulvis, wafer, injection liquid or suspensoid, teaspoon agent, soupspoon agent etc. and their the multiple doses form of separating.
Embodiment
The present invention is illustrated in following examples plan.
Experimental section
The preparation midbody compound
Embodiment A 1
A) with 1,2,3,4-tetrahydrochysene [1] thionaphthene also [3,2-c] pyridine HCl (1: 1) (0.02mol), 1,1-dimethyl ethyl (4-chlorobutyl) carbamate (0.044mol), Na
2CO
3(0.05mol) and the mixture of KI (catalytic amount) in 4-methyl-2 pentanone (200ml) stir and reflux and spend the night, be cooled to room temperature and evaporating solvent then.Wash resistates with water and with CH
2Cl
2Extract.Dry isolating organic layer filters and evaporating solvent.Through silica gel column chromatography (elutriant: CH
2Cl
2/ CH
3OH 90/10) the purifying resistates.The part of collection requirement and evaporating solvent obtain 1, and the 1-dimethyl ethyl [4-(3,4-dihydro [1] thionaphthene is [3,2-c] pyridines-2 (1H)-yl) butyl also] carbamate (intermediate 1).
B) will the intermediate (1) in the HCl/2-propyl alcohol (20ml) (0.02mol) and the mixture of 2-propyl alcohol (150ml) stir and refluxed 30 minutes, be cooled to room temperature then.Leach precipitation and dry, obtain 3 of 4.9g, 4-dihydro [1] thionaphthene is [3,2-c] pyridines-2 (1H)-butylamine dihydrochloride (73%) (intermediate 2) also.
Embodiment A 2
A) butyllithium (2.5M) (0.27mol) is added dropwise in 6-methoxyl group benzo [b] thiophene (0.25mol) in tetrahydrofuran (THF) (1000ml), stirs down at-30 ℃.Under-30 ℃, mixture was stirred 10 minutes.Under-30 ℃, be added dropwise to oxyethane (0.38mol is in the 100ml tetrahydrofuran (THF)).Make mixture be warmed to room temperature and stirred 3 hours.With this mixture of rare HCl solution acidifying.Evaporating solvent.The dilute with water resistates is also used CH
2Cl
2Extract this mixture.Dry isolating organic layer filters and evaporating solvent.In hexane, stir resistates, leach and drying, obtain 6-methoxyl group benzo [b] Thiophene-2-Ethanol (intermediate 3) of 41.3g.
B) methylsulfonyl chloride (0.21mol) is joined intermediate (3) (0.19mol) and N, N-diethyl ethamine (0.21mol) is at CH
2Cl
2In the mixture (1L), stir down at 0 ℃.At room temperature, reaction mixture was stirred 4 hours, be poured in the water then.Dry isolating organic layer filters and evaporating solvent.Grinding residues in Di Iso Propyl Ether is filtered and drying, obtains 6-methoxyl group benzo [b] the Thiophene-2-Ethanol methanesulfonates (intermediate 4) of 50.5g.
C) with intermediate (4) (0.18mol) and the mixture of sodium iodide (0.45mol) in 2-acetone (1000ml) stir and refluxed 9 hours, be cooled to room temperature and evaporating solvent then.Wash resistates with water and use CH
2Cl
2Extract.Dry isolating organic layer filters and evaporating solvent, obtains 2-(2-iodo ethyl)-6-methoxyl group benzo [b] thiophene (intermediate 5) of 57g.
D) intermediate (5) (0.18mol) is joined 1,3,5 in batches, 7-four aza-tricycles [3.3.1.13,7] decane (0.45mol) are at CHCl
3In the mixture (600ml).Reaction mixture stirring and backflow are spent the night, be cooled to room temperature then.Leach precipitation and dry, obtain 1-[2-(6-methoxyl group benzo [b] thiophene-2-yl) ethyl of 54.2 g]-1,3,5,7-four aza-tricycles [5.1.1.1-5,7] iodide in the last of the ten Heavenly stems (intermediate 6).
E) at room temperature, with intermediate (6) (0.12mol) and the mixture of HCl (0.50mol) in ethanol (171ml) stirred 2 days.Add more HCl (10ml) and ethanol (40ml) and stirred reaction mixture and refluxed 1 hour, be cooled to room temperature then.Evaporating solvent.In the 2-propyl alcohol, stir resistates, leach then.Drying solid also is converted into free alkali again with 20% NaOH.Dry isolating organic layer filters and evaporating solvent.Resistates is dissolved in the 2-propyl alcohol and is converted into hydrochloride (1: 1) with the HCl/2-propyl alcohol.Leach precipitation and dry, obtain 1,2,3 of 13.1g, 4-tetrahydrochysene-7-methoxyl group [1] thionaphthene is [3,2-c] pyridines (50%) (intermediate 7) also.Also with similar method preparation:
1,2,3,4-tetrahydrochysene-8-methyl-[1] thionaphthene is [3,2-c] pyridine hydrochlorides (1: 1) (intermediate 8) also; With
1,2,3,4-tetrahydrochysene-8-fluoro-[1] thionaphthene is [3,2-c] pyridine hydrochlorides (1: 1) (intermediate 9) preparation formulas (I) compound also
Embodiment B 1
With 1,2,3,4-tetrahydrochysene-thionaphthene also [3,2-c] pyridine [according at J.Am.Chem.Soc., 1953, the similar approach preparation of describing in the 697th page] (0.009mol), 3-(2-chloro-ethyl)-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one (0.011mol), Na
2CO
3(0.023mol) and the mixture of KI (catalytic amount) in methyl iso-butyl ketone (MIBK) (100ml) stir and reflux and spend the night, be cooled to room temperature and evaporating solvent then.Wash resistates with water and with CH
2Cl
2Extract.Dry isolating organic layer filters and evaporating solvent.Through silica gel column chromatography (elutriant: CH
2Cl
2/ CH
3OH 90/10) the purifying resistates.The part of collection requirement and evaporating solvent.Resistates is converted into (E)-2-butylene diacid salt (2: 1).Leach precipitation and dry, obtain 2.3g (47%) 3-[2-(3,4-dihydro-[1] thionaphthene is [3,2-c] pyridines-2 (1H)-yl) ethyl also]-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one (E)-2-butylene diacid salt (2: 1) (compound 1).
Embodiment B 2
With Na
2CO
3(0.100g) join 1,2,3,4-tetrahydrochysene-thionaphthene also [3,2-c]-pyridine (0.00044mol) and 3-(4-chlorobutyl)-2, (1H's 4-3H) in the solution of quinazoline diones (0.100g) in methyl iso-butyl ketone (MIBK) (2ml) and under 100 ℃ spends the night the reaction mixture stirring that generates.The compound of separation requirement and through the HPLC (elutriant: CH of Kromasil Spherical underivatized silica gel
2Cl
2/ (CH
2Cl
2/ CH
3OH 90/10)/CH
3OH (0 minute) 100/0/0, (10.5 minutes) 0/100/0, (12.5 minutes) 50/0/50, (14.00 minutes) 0/0/100, (15.01-20.00 minute) 100/0/0) purifying.Collect pure part and evaporating solvent, obtain 0.025g 3-[4-(3,4-dihydro-[1] thionaphthene is [3,2-c] pyridines-2 (1H)-yl) butyl also]-1,3-quinazoline-2,4 (1H, 3H)-diketone (compound 6).
Embodiment B 3
With intermediate (2) (0.01mol), 2-chloro benzothiazole (0.012mol) and Na
2CO
3(0.015mol) mixture in cellosolvo (50ml) stirs and refluxes and spend the night.The heat filtering reaction mixture also is cooled to room temperature with filtrate.Evaporating solvent.Through silica gel column chromatography (elutriant: CH
2Cl
2/ CH
3OH 90/10) the purifying resistates.The part of collection requirement and evaporating solvent.Resistates is converted into its hydrochloride (1: 2).Leach precipitation and dry, obtain the N-2-benzothiazolyl-3 of 2.3g, 4-dihydro [1] thionaphthene is [3,2-c] pyridines-2 (1H)-butylamine dihydrochloride (49%) (compound 18) also.
Table 1 is listed formula (I) compound, and they can use the similar approach preparation with one of above embodiment.
C. pharmacology embodiment
Embodiment C .1: to α
2The external binding affinity of acceptor
The external beam radiotherapy aglucon in conjunction with the experiment in, bounds evaluation (I) compound and α
2The interaction of acceptor.
The radioligand that special receptor is had a lower concentration of high binding affinity is generally hatched with the sample of the tissue preparation liquid of enrichment in special receptor or is hatched with the goods of the cell of people's acceptor of cloning by expression in buffer culture medium.Between incubation period, radiative aglycone combination is to acceptor.When reaching balance, the receptors bind radioactivity is separated with binding radioactivity not, and receptor-binding activity is counted.In competitive binding experiment, the interaction of evaluation test compound and this receptor.The test compound of multiple concentration is joined in the mixtures incubated that contains acceptor goods and radioligand.In its binding affinity and the combination that suppresses radioligand of the test compound of the ratio of its concentration.
Be used for α
2A, α
2BAnd α
2CThe radioligand of receptors bind is
3H-square-bottomed bamboo basket cottonrose hibiscus plain and the acceptor goods that use be the people α of cloning by expression
2A, α
2BAnd α
2CThe Chinese hamster ovary of acceptor (CHO) cell.
At the compound of above experimental section illustrated in three kinds of acceptors each is all had at least 10
-6The IC of M
50Value (i.e. the repressed concentration of 50% acceptor).
D. composition embodiment
(A.I.) relate to formula (I) compound, their pharmaceutically acceptable addition salt or form of three-dimensional chemical isomer as " activeconstituents " that in all these embodiment, use.
Embodiment is D.1: capsule
With A.I., 6g sodium lauryl sulphate, 56g starch, 56g lactose, 0.8g colloidal silica and the 1.2g Magnesium Stearate of 20g vigorous stirring together.Subsequently the mixture that generates is filled in 1000 suitable hard gelatin capsules every A.I. that contains 20mg.
Embodiment is D.2: film coating tablet
The preparation label
With A.I., 570g lactose and the 200g starch thorough mixing of 100g, use 5g sodium lauryl sulphate and the 10g polyvinylpyrrolidone solution-wet in about 200ml water then.Moist powdered mixture is sieved, and drying is also sieved once more.Add 100g Microcrystalline Cellulose and 15g hydrogenated vegetable oil then.With whole thorough mixing and be pressed into tablet, obtain 10,000, every contains the 10mg activeconstituents.
Dressing
In the solution of 10g methylcellulose gum in the 75ml Denatured alcohol, add the solution of 5g ethyl cellulose in the 150ml methylene dichloride.Add 1,2 of 75ml methylene dichloride and 2.5ml then, the 3-glycerol.The fusion of 10g polyoxyethylene glycol and be dissolved in the 75ml methylene dichloride.The latter solution is joined in the former solution, add the dense painted suspension of 2.5g Magnesium Stearate, 5g polyvinylpyrrolidone and 30ml then and make whole homogenizing.In coating device, use the mixture that obtains thus the label dressing.
Embodiment is D.3: oral solution
The 4-methyl hydroxybenzoate of 9g and the 4-nipasol of 1g are dissolved in the 41 ebullient purified water.In 31 these solution, at first dissolve the 2,3 dihydroxybutanedioic acid of 10g, dissolve the A.I. of 20g then.The latter solution mixed with the remainder of former solution and to wherein add 121 1,2,70% solution of 3-glycerol and 31 sorbyl alcohols.Be dissolved in the 40g soluble saccharin in 0.51 water and add the 2ml raspberry and 2ml gooseberry essence.The latter solution is mixed with former solution, add water to the volume of 20l in right amount, the oral liquid that comprises every (5ml) 5mg activeconstituents is provided.The solution that generates is filled in the suitable container.
Embodiment is D.4: injection solution
The 4-methyl hydroxybenzoate of 1.8g and the 4-nipasol of 0.2g are dissolved in about 0.51 ebullient water for injection.After being cooled to about 50 ℃, following and stir the A.I. that adds 4g lactic acid, 0.05g propylene glycol and 4g down.Described solution is cooled to room temperature and additional with an amount of water for injection, adds to the 1l volume, obtain comprising the solution of 4mg/ml A.I..With this solution filtration sterilization and be filled in the sterilising vessel.
Claims (8)
1. following formula: compound, their pharmaceutically acceptable addition salt or form of three-dimensional chemical isomer,
Wherein:
Each R
1Independent is hydrogen, halogen or C
1-4Alkoxyl group;
Alk is C
1-6Alkane 2 basis;
N is 1;
P is 0;
D is the group of following formula:
Wherein
Each X independently represents S;
R
2Be C
1-6Alkyl, aryl or aryl C
1-6Alkyl;
R
5, R
6, R
7, R
8, R
10Each independently is hydrogen or C
1-6Alkyl; Or
R
3And R
4Can form the divalent group-R of following formula together
3-R
4-:
-CH=CH-CH=CH-(a-5); Or
-S-CH=CH-(a-8); With aryl be phenyl.
2. the compound of claim 1, wherein Alk is 1,2-ethane two bases, 1,3-propane two bases or 1,4-butane two bases.
3. the compound of claim 1, wherein n is 1 and R
1Be hydrogen, chlorine, fluorine or methoxyl group.
4. the compound of claim 1, wherein said compound is selected from:
5. the compound of claim 1 is used for the treatment of by maincenter α in preparation
2-beta-2-adrenoreceptor mediated dysthymia disorders or the purposes in the Parkinsonian medicine.
6. composition, it comprises pharmaceutically acceptable carrier and as the compound of claim 1 activeconstituents, the treatment significant quantity.
7. the method for compositions of preparation claim 6 is mixed into mixture by the compound and the pharmaceutically acceptable carrier that will define as the claim 1 of activeconstituents.
8. be used to prepare the method for the compound of claim 1, it is characterized in that:
A) in the presence of alkali and optionally in the presence of catalyzer, in The suitable solvent, with also [3,2-c] pyridine derivate N-alkylation of thionaphthene of formula (III) alkylating reagent wushu (II),
W wherein
1The reaction leavings group that expression is suitable, D, Alk, p, n and R
1In in claim 1, define; Or
C) use wherein W
3Be the amine N-alkylation of formula (VII) the intermediate wushu (VI) of suitable reaction leavings group,
Wherein X, R
10, Alk, p, n and R
1Just like the definition in the claim 1; With
D) optionally, according to method for transformation known in the art formula (I) compound is transformed each other, and in addition optionally, by transforming into acid salt therapeutic activity, atoxic with acid treatment wushu (I) compound, or by transforming into base addition salt therapeutic activity, atoxic with alkaline purification wushu (I) compound, perhaps opposite, by described acid salt form being transformed into free alkali with alkaline purification, or by with acid treatment described base addition salt being transformed into free acid; And, optionally, prepare their form of three-dimensional chemical isomer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203363.1 | 1998-10-06 | ||
| EP98203363 | 1998-10-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1321159A CN1321159A (en) | 2001-11-07 |
| CN1158287C true CN1158287C (en) | 2004-07-21 |
Family
ID=8234188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998116777A Expired - Fee Related CN1158287C (en) | 1998-10-06 | 1999-10-01 | Benzothieno [3,2-c]pyridines as alpha 2-antagonists |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6426350B1 (en) |
| EP (1) | EP1117667B1 (en) |
| JP (1) | JP4580555B2 (en) |
| KR (1) | KR20010071828A (en) |
| CN (1) | CN1158287C (en) |
| AR (1) | AR023678A1 (en) |
| AT (1) | ATE363485T1 (en) |
| AU (1) | AU760226B2 (en) |
| BG (1) | BG64625B1 (en) |
| BR (1) | BR9913110A (en) |
| CA (1) | CA2346084C (en) |
| CZ (1) | CZ20011103A3 (en) |
| DE (1) | DE69936219T2 (en) |
| EE (1) | EE04835B1 (en) |
| ES (1) | ES2288025T3 (en) |
| HK (1) | HK1039113A1 (en) |
| HU (1) | HUP0103612A3 (en) |
| ID (1) | ID28280A (en) |
| IL (2) | IL142442A0 (en) |
| NO (1) | NO20011309D0 (en) |
| NZ (1) | NZ509911A (en) |
| PL (1) | PL347184A1 (en) |
| RU (1) | RU2222542C2 (en) |
| SK (1) | SK4312001A3 (en) |
| TR (1) | TR200100954T2 (en) |
| TW (1) | TWI251595B (en) |
| UA (1) | UA70334C2 (en) |
| WO (1) | WO2000020422A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003219029B2 (en) * | 2002-03-08 | 2008-09-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V | Use of EGFR transactivation inhibitors in human cancer |
| CA2480266C (en) * | 2002-04-03 | 2011-07-12 | Orion Corporation | Use of an alpha2-adrenoreceptor antagonist for cns-related diseases |
| WO2005100355A1 (en) | 2004-04-12 | 2005-10-27 | Taisho Pharmaceutical Co., Ltd. | Cyclic amine compound |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3752820A (en) | 1972-03-20 | 1973-08-14 | Colgate Palmolive Co | Substituted-1,2,3,4-tetrahydrobenzothieno(3,2-c)pyridine derivatives |
| FR2570701B1 (en) | 1984-09-27 | 1987-05-22 | Synthelabo | FURO (3,2-C) PYRIDINES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US4686226A (en) | 1985-09-03 | 1987-08-11 | Merck & Co., Inc. | Substituted benzo[b]furo- and benzo[b]thieno quinolizines |
| EP0339959A3 (en) | 1988-04-27 | 1991-03-20 | Glaxo Group Limited | Lactam derivatives |
| US5100891A (en) * | 1991-01-18 | 1992-03-31 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[B]indoles and related compounds |
| ATE247114T1 (en) * | 1994-09-12 | 2003-08-15 | Lilly Co Eli | SEROTONERGIC MODULATORS |
| JP3274579B2 (en) * | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | Agent for treating psychiatric symptoms associated with cerebrovascular disorders |
| UA52681C2 (en) | 1997-04-08 | 2003-01-15 | Янссен Фармацевтика Н.В. | Derivatives of 1,2,3,4-tetrahydro-benzofuro [3,2,-c] pyridine |
-
1999
- 1999-01-10 UA UA2001031998A patent/UA70334C2/en unknown
- 1999-10-01 BR BR9913110-2A patent/BR9913110A/en not_active Application Discontinuation
- 1999-10-01 WO PCT/EP1999/007418 patent/WO2000020422A1/en active IP Right Grant
- 1999-10-01 CZ CZ20011103A patent/CZ20011103A3/en unknown
- 1999-10-01 HU HU0103612A patent/HUP0103612A3/en unknown
- 1999-10-01 TR TR2001/00954T patent/TR200100954T2/en unknown
- 1999-10-01 IL IL14244299A patent/IL142442A0/en active IP Right Grant
- 1999-10-01 JP JP2000574534A patent/JP4580555B2/en not_active Expired - Fee Related
- 1999-10-01 US US09/806,432 patent/US6426350B1/en not_active Expired - Lifetime
- 1999-10-01 SK SK431-2001A patent/SK4312001A3/en unknown
- 1999-10-01 KR KR1020017000400A patent/KR20010071828A/en active Search and Examination
- 1999-10-01 NZ NZ509911A patent/NZ509911A/en unknown
- 1999-10-01 DE DE69936219T patent/DE69936219T2/en not_active Expired - Lifetime
- 1999-10-01 EP EP99947469A patent/EP1117667B1/en not_active Expired - Lifetime
- 1999-10-01 ID IDW20010781A patent/ID28280A/en unknown
- 1999-10-01 AU AU60899/99A patent/AU760226B2/en not_active Ceased
- 1999-10-01 CA CA2346084A patent/CA2346084C/en not_active Expired - Fee Related
- 1999-10-01 EE EEP200100206A patent/EE04835B1/en not_active IP Right Cessation
- 1999-10-01 AT AT99947469T patent/ATE363485T1/en not_active IP Right Cessation
- 1999-10-01 PL PL99347184A patent/PL347184A1/en not_active Application Discontinuation
- 1999-10-01 TW TW088116899A patent/TWI251595B/en not_active IP Right Cessation
- 1999-10-01 RU RU2001111753/04A patent/RU2222542C2/en not_active IP Right Cessation
- 1999-10-01 CN CNB998116777A patent/CN1158287C/en not_active Expired - Fee Related
- 1999-10-01 ES ES99947469T patent/ES2288025T3/en not_active Expired - Lifetime
- 1999-10-05 AR ARP990105039A patent/AR023678A1/en active IP Right Grant
-
2001
- 2001-03-12 BG BG105331A patent/BG64625B1/en unknown
- 2001-03-15 NO NO20011309A patent/NO20011309D0/en not_active Application Discontinuation
- 2001-04-04 IL IL142442A patent/IL142442A/en not_active IP Right Cessation
- 2001-12-15 HK HK01108819A patent/HK1039113A1/en not_active IP Right Cessation
-
2002
- 2002-04-16 US US10/123,338 patent/US6774129B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1022566C (en) | Process for preparation of substituted 1-piperidylalkylene-pyridopyrimidone or thiazolpyrimidone | |
| CN1805938B (en) | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases | |
| CN1112365C (en) | Piperidine derivatives | |
| CN1042537A (en) | Carbostyril derivative | |
| CN1100779C (en) | 3-aryl substituted pyrazolo [4,3-d] pyrimidine derivatives, corticotropin-releasing factor receptor (CRT1) specific ligands | |
| CN1110496C (en) | Tetrahydro Gamma-carbolines | |
| CN1201461A (en) | Fused tropane-derivatives as neurotransmitter reuptake inhibitors | |
| CN1027506C (en) | 2,9-disubstituted-4H-pyrido {1,2-A} pyrimidin-4-ones | |
| CN100343257C (en) | CCR1 antagonists for the treatment of I.A. demyelinating inflammatory disease | |
| CN1037770C (en) | Substituted thiazolyl and substituted pyridinyl derivatives | |
| CN1097053C (en) | 1,2,3,4-tetrahydro-benzofuro [3,2-c] pyridine derivatives | |
| CN1131230C (en) | Tricyclic delta 3-piperidines as alpha 2-antagonists | |
| CN1152874C (en) | Antipsychotic 4 (1 H -indolyl -1 -YL) -1 -substituted piperidine derivatives | |
| CN1149996C (en) | Hexahydro-pyrido (4,3-B) indole derivatives as antipsychotic drugs | |
| CN101068787A (en) | 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists | |
| US20080214542A1 (en) | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | |
| TW201002702A (en) | Dibenzothiazepine derivatives and uses thereof | |
| CN1158287C (en) | Benzothieno [3,2-c]pyridines as alpha 2-antagonists | |
| CN1332740A (en) | 5HT antagonists for antidepressant therapy | |
| CN1131868C (en) | Tricyclic delta 3-piperidines as pharmaceuticals | |
| CN105189492A (en) | Ergoline derivatives as dopamine receptor modulators | |
| HU201543B (en) | Process for production of derivatives of 2-(/piperin-4-il/-methil/)-1,2,3,4-tetrahydro-izoquinoline and medical compositions containing them | |
| CN1043574C (en) | Heterocyclic amines having central nervous system activity | |
| CN1154646C (en) | Benzisozazoles and phenones as alpha antagonist | |
| JP4292738B2 (en) | Indole derivatives and their pharmaceutical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040721 Termination date: 20171001 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |